ProShares Trust (BIB)
Management Company · XNAS · Series S000018718 · View on SEC EDGAR ↗
$126.22
As of Aug. 19, 2026
▲ +14.24 (+12.71%)
1-day change
$54.56 – $126.40
52-week range
- Net assets
- $73.7M
- Holdings
- 267
- As of
- May 31, 2026
- Top 10 holdings weight
- 42.99%
- Effective number of positions
- 40.3
- Positions above 1%
- 20
On this page
- Price chart The fund's market price over time, with technical overlays.
- Performance Total return, volatility, drawdown and other risk metrics.
- Fund flows Money flowing in and out of the fund each month, from N-PORT filings.
- Holdings Every position the fund currently holds, with weights.
- Sector breakdown How the fund's holdings split across market sectors.
- Institutional owners 13F institutions that report holding this ETF.
- Similar funds Other funds with overlapping holdings or comparable size.
BIB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
Performance as of March 10, 2026
| Period | Price return | Total return |
|---|---|---|
| 1M | ▲ +1.07% | — |
| 3M | ▲ +7.05% | — |
| 6M | ▲ +49.02% | — |
| YTD | ▲ +6.58% | — |
| 1Y | ▲ +57.26% | — |
| 3Y | — | — |
| 5Y | — | — |
| Max since Feb. 27, 2024 | ▲ +36.57% | — |
- Volatility 1Y
- 45.98%
- Volatility 3Y
- —
- Max drawdown 3Y
- —
- Beta 3Y
- —
- Sharpe 1Y*
- 1.23
Total return is shown once dividend history for this fund has been collected — price return alone would duplicate it misleadingly. Returns are not benchmarked against an index. * Sharpe ratio is computed with a 0% risk-free rate.
Fund flows (SEC-reported)
- Last month (May 2026)
- -$4.8M
- Quarter ending May 2026
- -$13.9M
- Trailing 12 months
- -$12.0M
Jun 2025 – May 2026
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Full composition 267 holdings
| Name | CUSIP | Value | % | Balance | Category | Country |
|---|---|---|---|---|---|---|
| Legend Biotech Corp. | 52490G102 | $85K | 0.12 | 3,122 | EC | KY |
| Kodiak Sciences, Inc. | 50015M109 | $83K | 0.11 | 2,255 | EC | US |
| BioCryst Pharmaceuticals, Inc. | 09058V103 | $83K | 0.11 | 9,271 | EC | US |
| Kiniksa Pharmaceuticals International plc | — | $82K | 0.11 | 1,698 | EC | GB |
| Aurinia Pharmaceuticals, Inc. | 05156V102 | $75K | 0.10 | 4,914 | EC | CA |
| Ocular Therapeutix, Inc. | 67576A100 | $73K | 0.10 | 8,049 | EC | US |
| Novocure Ltd. | — | $72K | 0.10 | 4,209 | EC | JE |
| Pharvaris NV | — | $71K | 0.10 | 2,367 | EC | NL |
| Sionna Therapeutics, Inc. | 829401108 | $71K | 0.10 | 1,651 | EC | US |
| ADMA Biologics, Inc. | 000899104 | $70K | 0.10 | 8,805 | EC | US |
| Rapport Therapeutics, Inc. | 75383L102 | $70K | 0.09 | 1,764 | EC | US |
| Zymeworks, Inc. | 98985Y108 | $70K | 0.09 | 2,766 | EC | US |
| Recursion Pharmaceuticals, Inc. | 75629V104 | $69K | 0.09 | 19,297 | EC | US |
| Sarepta Therapeutics, Inc. | 803607100 | $69K | 0.09 | 3,875 | EC | US |
| AbCellera Biologics, Inc. | 00288U106 | $69K | 0.09 | 11,209 | EC | CA |
| Harmony Biosciences Holdings, Inc. | 413197104 | $68K | 0.09 | 2,140 | EC | US |
| Nurix Therapeutics, Inc. | 67080M103 | $68K | 0.09 | 3,802 | EC | US |
| Trevi Therapeutics, Inc. | 89532M101 | $67K | 0.09 | 4,742 | EC | US |
| Novavax, Inc. | 670002401 | $66K | 0.09 | 6,023 | EC | US |
| Tyra Biosciences, Inc. | 90240B106 | $66K | 0.09 | 1,974 | EC | US |
| uniQure NV | — | $66K | 0.09 | 2,305 | EC | NL |
| Stoke Therapeutics, Inc. | 86150R107 | $65K | 0.09 | 2,111 | EC | US |
| ANI Pharmaceuticals, Inc. | 00182C103 | $65K | 0.09 | 830 | EC | US |
| Syndax Pharmaceuticals, Inc. | 87164F105 | $64K | 0.09 | 3,261 | EC | US |
| Agios Pharmaceuticals, Inc. | 00847X104 | $64K | 0.09 | 2,166 | EC | US |
| Genmab A/S | 372303206 | $63K | 0.09 | 2,379 | EC | DK |
| Vericel Corp. | 92346J108 | $62K | 0.08 | 1,875 | EC | US |
| Iovance Biotherapeutics, Inc. | 462260100 | $62K | 0.08 | 15,232 | EC | US |
| Intellia Therapeutics, Inc. | 45826J105 | $61K | 0.08 | 4,369 | EC | US |
| AtaiBeckley, Inc. | 04650F101 | $61K | 0.08 | 13,429 | EC | US |
| Taysha Gene Therapies, Inc. | 877619106 | $59K | 0.08 | 10,128 | EC | US |
| Innoviva, Inc. | 45781M101 | $59K | 0.08 | 2,740 | EC | US |
| Amylyx Pharmaceuticals, Inc. | 03237H101 | $58K | 0.08 | 4,059 | EC | US |
| AnaptysBio, Inc. | 032724106 | $57K | 0.08 | 1,023 | EC | US |
| Precigen, Inc. | 74017N105 | $57K | 0.08 | 13,080 | EC | US |
| Inhibrx Biosciences, Inc. | 45720N103 | $56K | 0.08 | 537 | EC | US |
| Monte Rosa Therapeutics, Inc. | 61225M102 | $56K | 0.08 | 2,818 | EC | US |
| Vir Biotechnology, Inc. | 92764N102 | $55K | 0.08 | 5,810 | EC | US |
| GH Research plc | — | $55K | 0.07 | 2,294 | EC | IE |
| Ardelyx, Inc. | 039697107 | $55K | 0.07 | 9,066 | EC | US |
| Fortrea Holdings, Inc. | 34965K107 | $53K | 0.07 | 3,455 | EC | US |
| MBX Biosciences, Inc. | 55287L101 | $52K | 0.07 | 1,658 | EC | US |
| Bicara Therapeutics, Inc. | 055477103 | $51K | 0.07 | 2,343 | EC | US |
| KalVista Pharmaceuticals, Inc. | 483497103 | $50K | 0.07 | 1,870 | EC | US |
| Septerna, Inc. | 81734D104 | $50K | 0.07 | 1,657 | EC | US |
| UroGen Pharma Ltd. | — | $49K | 0.07 | 1,730 | EC | IL |
| Harrow, Inc. | 415858109 | $48K | 0.07 | 1,370 | EC | US |
| Maze Therapeutics, Inc. | 578784100 | $47K | 0.06 | 1,778 | EC | US |
| Immunocore Holdings plc | 45258D105 | $47K | 0.06 | 1,621 | EC | GB |
| ArriVent Biopharma, Inc. | 04272N102 | $46K | 0.06 | 1,527 | EC | US |
Page 3
of 6
Sector breakdown
Healthcare
64.1%
Other/Unmapped
35.9%
Institutional owners (13F) 22 filers
Institutions that report holding this ETF in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| Institution | Value | % of tracked 13F | Shares | Type | As of |
|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $785,973 | 21.94% | 7,802 | Shares | June 30, 2026 |
| Capital Investment Advisors, LLC | $599,013 | 16.72% | 5,946 | Shares | June 30, 2026 |
| Kaizen Financial Strategies | $535,554 | 14.95% | 5,315 | Shares | June 30, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $413,034 | 11.53% | 4,100 | Call option | June 30, 2026 |
| Palumbo Wealth Management LLC | $402,960 | 11.25% | 4,000 | Shares | June 30, 2026 |
| CITADEL ADVISORS LLC | $302,220 | 8.44% | 3,000 | Call option | June 30, 2026 |
| Jump Financial, LLC | $257,189 | 7.18% | 2,553 | Shares | June 30, 2026 |
| TOTH FINANCIAL ADVISORY CORP | $102,957 | 2.87% | 1,022 | Shares | June 30, 2026 |
| FRANKLIN RESOURCES INC | $70,115 | 1.96% | 696 | Shares | June 30, 2026 |
| PNC Financial Services Group, Inc. | $50,370 | 1.41% | 500 | Shares | June 30, 2026 |
| Ashton Thomas Private Wealth, LLC | $37,576 | 1.05% | 373 | Shares | June 30, 2026 |
| Truvestments Capital LLC | $12,593 | 0.35% | 125 | Shares | June 30, 2026 |
| Axiom Investment Management LLC | $5,037 | 0.14% | 50 | Shares | June 30, 2026 |
| Qube Research & Technologies Ltd | $4,936 | 0.14% | 49 | Shares | June 30, 2026 |
| SIMPLEX TRADING, LLC | $1,309 | 0.04% | 13 | Shares | June 30, 2026 |
| CHASE INVESTMENT COUNSEL CORP | $241 | 0.01% | 2,400 | Shares | June 30, 2026 |
| Rockefeller Capital Management L.P. | $201 | 0.01% | 2 | Shares | June 30, 2026 |
| MORGAN STANLEY | $131 | 0.00% | 1 | Shares | June 30, 2026 |
| UBS Group AG | $101 | 0.00% | 1 | Shares | June 30, 2026 |
| WELLS FARGO & COMPANY/MN | $65 | 0.00% | 1 | Shares | June 30, 2026 |
| Harel Insurance Investments & Financial Services Ltd. | $20 | 0.00% | 198 | Shares | June 30, 2026 |
| ROYAL BANK OF CANADA | $0 | 0.00% | 1 | Shares | June 30, 2026 |
Peer funds
More from this issuer
Similar by size
| Fund | AUM |
|---|---|
| AMUU Direxion Shares ETF Trust | $74.2M |
| DTEC ALPS ETF Trust | $74.4M |
| ENZL iShares Trust | $74.5M |
| DIG ProShares Trust | $74.6M |
| XOCT First Trust Exchange-Traded Fun… | $74.9M |
| ITDE iShares Trust | $73.3M |
| EIRL iShares Trust | $72.8M |
| FDIV EA Series Trust | $72.7M |
| DBEZ DBX ETF Trust | $72.7M |
| ITDB iShares Trust | $72.6M |